Mysterious Perlmutter-Helmed Start-Up Eikon Raises $517.8m
New Executive Team Members Also Announced
Eikon launched in 2021 with $148m in series A venture capital and former Merck R&D head Roger Perlmutter as its CEO, but even with half a billion dollars in fresh cash, the firm has not revealed its therapeutic focus.
You may also be interested in...
It is time for In Vivo's 15th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
Longtime R&D leader Roy Baynes is leaving Merck to become chief medical officer at the biotech start-up helmed by Merck's former R&D chief Roger Perlmutter.
Private Company Edition: Dyno’s first VC round will enable more deals for its novel AAV platform; Eikon pioneers new drug discovery technology. Also, Treeline’s early funding revealed at $211.7m; Capsida raised $140m from a VC round, AbbVie deal; and Affinia closed a $110m series B round.